AbbVie Inc. (ABBV) News and Biopharmaceutical & Healthcare Updates
AbbVie Inc., headquartered in North Chicago, Illinois, develops advanced therapies in immunology, oncology, neuroscience, eye care, and medical aesthetics. Its key products include Humira, Skyrizi, and Botox (via Allergan). AbbVie focuses on research-driven innovation and expanding patient access to next-generation treatments worldwide.
281.04
4.59
1.66 %
At close
10/12
USD
Daily range
276.63
281.04
281.04
Weekly range
260.89
281.04
281.04
AbbVie shares weekly forecast: Ongoing consolidation supported by Ichimoku Kijun level at $262.5
Shares of AbbVie Inc. (ABBV) are trading near $279 as the recovery setup persists, but momentum is increasingly stretched. The small upside this week reflects a ...
Why is AbbVie stock up 1.8% today?
AbbVie Inc. (ABBV) is climbing 1.82% after securing two FDA Breakthrough Therapy Designations for its oncology candidate telisotuzumab adizutecan, supporting strong buying interest. This move is ...
Why are AbbVie shares down 2% today?
AbbVie Inc. (ABBV) fell 2.03% following a series of positive corporate announcements, including regulatory milestones and strong earnings, even as selling pressure persisted after a downside gap. ...
Epcoritamab plus R-CHOP Phase 3 results: Can AbbVie stock break $279.47 resistance?
AbbVie Inc. (ABBV) stock is trading at $274.75, up 3.02% for the day. The price stands firmly above its key moving averages, reflecting strong near-term ...
AbbVie stock weekly forecast: Holds gains as buyers stay in control
Shares of AbbVie Inc. (ABBV) are holding near $262 as buyers remain in control, keeping the recent price action stable despite limited movement over the past week. With ...
AbbVie shares weekly forecast: recovery holds but faces a stretched setup
Shares of AbbVie Inc. (ABBV) are trading near $265 as a cautious recovery setup remains in place, with price action holding steady within a stretched short-term range. ...
AbbVie stock edges lower after European Commission approval for pJIA treatment
AbbVie said the European Commission has approved its treatment for active polyarticular juvenile idiopathic arthritis in children as young as two who have not responded to DMARDs. Shares edge ...
AbbVie shares weekly forecast: Corporate news flow supports steady climb but resistance caps upside
Shares of AbbVie Inc. (ABBV) are trading near $266 as a slow upward grind keeps the recovery intact, with conditions now looking stretched at the top of the recent ...
AbbVie announces collaboration agreement with Iambic: Can ABBV break above $266.24?
AbbVie announced a partnership with Iambic to accelerate AI-driven drug discovery in immunology, neuroscience and oncology. The stock is little changed on the day, trading near $263.78.AbbVie ...
AbbVie stock faces resistance at $254.08 with bounce potential in focus: weekly analysis
Shares of AbbVie Inc. (ABBV) are trading near $252 as a more than 1.5% decline stretched the stock into oversold territory last week. Conflicting signals from momentum ...
What's behind AbbVie's latest 2.3% stock pullback?
AbbVie Inc. (ABBV) fell 2.28% after the company reported strong second-quarter 2026 results and completed the acquisition of Apogee Therapeutics, integrating zumilokibart into its portfolio. The ...
AbbVie stock weekly forecast: Upward momentum continues amid positive sentiment and Apogee acquisition
Shares of AbbVie Inc. (ABBV) are holding near $260 after gaining just over 1.5% over the past week as buyers keep control. Momentum has been supported by steady inflows ...
AbbVie stock weekly forecast: support at $254.34 under scrutiny as sellers press recent lows
Shares of AbbVie Inc. (ABBV) are trading near $259 after slipping nearly 3% over the past week, as recovery attempts hold but look stretched. Corporate updates and ...
AbbVie submits EMA application for subcutaneous Crohns induction after stock ends session down 1.1%
AbbVie said it had submitted an application to the European Medicines Agency for subcutaneous induction of one of its medicines in Crohns disease on August 21, 2026. The stock is down 1.1% on the ...
AbbVie shares fall around 1.5% as strong Q2 2026 results fail to lift sentiment
AbbVie Inc. (ABBV) slid 1.55% after opening with downside pressure, even as strong Q2 2026 earnings and an increased full-year EPS guidance served as the session's primary backdrop. The move is ...
ABBV climbs around 1.5% after double-digit revenue growth and Apogee acquisition
AbbVie Inc. (ABBV) climbed 1.58% after reporting strong financial performance and robust sales growth in its key immunology portfolio. The advance is supported by a bullish technical structure, ...
AbbVie shares weekly forecast: Recovery holds but faces a stretched setup
Shares of AbbVie Inc. (ABBV) are trading near $266 after climbing nearly 6% over the past week, driven by steady optimism around its recovery setup. Corporate momentum ...
AbbVie stock outlook: Haisco global licensing agreement expands pipeline
AbbVie Inc. (ABBV) stock is trading at $266.83, marking a daily advance of 3.05%. The stock sits comfortably above its key moving averages, reflecting continued strength ...
Will AbbVie stock break $262.58 resistance after global licensing deal with Haisco?
AbbVie (ABBV) stock is trading at $258.09, up 3.09% for the session. The price remains above its key moving averages, indicating sustained momentum relative to recent ...
AbbVie stock faces volatility with earnings strength but resistance remains in focus: weekly analysis
Shares of AbbVie Inc. (ABBV) are trading near $249 after climbing around 1.4% over the past week. Buyers are struggling to regain firm control as the chart shows ...
AbbVie stock decline stretches into oversold territory: weekly analysis
Shares of AbbVie Inc. (ABBV) are trading near $249 after a stretch of steady declines pushed technical readings into oversold territory. Momentum is mixed, with oversold ...
